Impact of Universal<i>Haemophilus influenzae</i>Type b Vaccination Starting at 2 Months of Age in the United States: An Economic Analysis

Abstract

Regardless of the perspective (direct cost or societal) and the assumptions used, the benefit-cost ratios of the US vaccination program are >1.0. Potential changes in the program, including use of more or less Hib combination vaccines, would not significantly alter the benefit-cost ratio. The national Hib vaccination program is highly cost beneficial and results in substantial cost savings.